Role of cyclic nucleotide phosphodiesterase isoenzymes in contractile responses of denuded rat aorta related to various Ca2+ sources

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 363, Issue 6, 2001, Pages 612-619

  Noguera, Maria Antonia ^a   Ivorra, Maria Dolores ^a   Lugnier, Claire ^b   D'Ocon, Pilar ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Biochemical functional correlation; Ca2+ sources; Cyclic nucleotide phosphodiesterases; KCl; Noradrenaline

Indexed keywords

5 (4 ACETAMIDOPHENYL) 2(1H) PYRAZINONE; CALCIUM ION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ISOBUTYLMETHYLXANTHINE; N CYCLOHEXYL 4 (1,2 DIHYDRO 2 OXO 6 QUINOLYLOXY) N METHYLVALERAMIDE; NIMODIPINE; NORADRENALIN; POTASSIUM CHLORIDE; ROLIPRAM; ZAPRINAST;

ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; EXTRACELLULAR CALCIUM; NONHUMAN; RAT; SMOOTH MUSCLE CONTRACTILITY;

1-METHYL-3-ISOBUTYLXANTHINE; 2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; ANIMALS; AORTA; CALCIUM; ISOENZYMES; MUSCLE, SMOOTH, VASCULAR; PHOSPHODIESTERASE INHIBITORS; PURINONES; RATS; RATS, WISTAR; ROLIPRAM; VASOCONSTRICTION;

EID: 0035000814     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002100100397     Document Type: Article

References (28)

1. Beavo JA (1990) Multiple phosphodiesterase isoenzymes: background, nomenclature and implications. In: Houslay MD (ed) Molecular pharmacology of cell regulation, vol 2. Wiley, Chichester, pp 3-15
2. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
3. Coste H, Grondin P (1995) Characterization of a novel potent and specific inhibitor of type V phosphodiesterase. Biochem Pharmacol 50:1577-1585
4. Delpy E, Coste H, Le Monnier de Gouville AC (1996) Effects of cyclic GMP elevation on isoprenaline-induced increase in cAMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3. Br J Pharmacol 119:471-478
5. Eckly AE, Lugnier C (1994) Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway. Br J Pharmacol 113:445-450
6. Eckly-Michel A, Martin V, Lugnier C (1997) Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP mediated vasorelaxation. Br J Pharmacol 122:158-164
7. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288:373-376
8. Hall IP (1993) Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses. Br J Clin Pharmacol 35:1-7
9. 2+ mobilization in smooth muscle of rabbit mesenteric artery. Br J Pharmacol 110:1117-1125
10. Ivorra DM, Le Bec A, Lugnier C (1992) Characterization of membrane-bound cyclic nucleotide phosphodiesterases from bovine aortic smooth muscle. J Cardiovasc Pharmacol 19:532-540
11. Keravis TM, Wells JM, Hardman JG (1980) Cyclic nucleotide PDE activities from pig coronary arteries. Lack of interconvertibility of major forms. Biochim Biophys Acta 613:116-129
12. Komas N, Lugnier C, Stoclet JC (1991a) Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 104:495-503
13. Komas N, Lugnier C, Andriantsitohaina R, Stoclet JC (1991b) Characterization of cyclic nucleotide phosphodiesterases from rat mesenteric artery. Eur J Pharmacol 208:85-87
14. Liu H, Maurice DH (1998) Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125:1501-1510
15. Lugnier C, Komas N (1993) Regulation of vascular cyclic nucleotide phosphodiesterases by cGMP: role in vasodilatation. Eur Heart J 14:141-148
16. Lugnier C, Bruch M, Stoclet JC, Strub MP, Marivet M, Wermuth CG (1985) Substituted carbostyrils as inhibitors of cyclic AMP phosphodiesterase. Eur J Med Chem 20:121-125
17. Lugnier C, Schoeffter P, Le Bec A, Strouthou L, Stoclet JC (1986) Selective inhibition of cyclic nucleotide phosphodiesterase of human, bovine and rat aorta. Biochem Pharmacol 35:1743-1751
18. 2+ stores mobilized by noradrenaline and caffeine in vascular smooth muscle. Naunyn-Schmiedeberg's Arch Pharmacol 345:333-341
19. Noguera MA, D'Ocon MP (1993) Evidence that depletion of internal calcium stores sensitive to noradrenaline elicits a contractile response dependent on extracellular calcium in rat aorta. Br J Pharmacol 110:861-867
20. 1-adrenoceptors in rat aorta. Naunyn-Schmiedeberg's Arch Pharmacol 356:83-89
21. Rascon A, Lindgren S, Stavenow L, Belfrage P, Andersson KE, Manganiello VC, Dergerman E (1992) Purification and properties of the GMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. Biochim Biophys Acta 1134: 149-156
22. Saeki T, Saito Y (1993) Isolation of cyclic nucleotide phosphodiesterase isozymes from pig aorta. Biochem Pharmacol 46:833-839
23. Schächtele C, Wagner B, Marmé D (1987) Stereoselective inhibition of calmodulin-dependent cAMP phosphodiesterase from bovine heart by (+)-and (-)-nimodipine. Naunyn-Schmiedeberg's Arch Pharmacol 335:340-343
24. i and force in middle cerebral artery of the rabbit. Br J Pharmacol 123:869-878
25. Stoclet JC, Keravis T, Komas N, Lugnier C (1995) Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiovascular diseases. Exp Opin Invest Drugs 4:1081-1100
26. Tomkinson A, Raeburn D (1996) The effect of isoenzyme-selective PDE inhibitors on methacholine-induced contraction of guinea-pig and rat ileum. Br J Pharmacol 118:2131-2139
27. Trochu JN, Leblais V, Rautureau Y, Bévérelli F, Le Marec H, Berdeaux A, Gautier C (1999) Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br J Pharmacol 128: 69-76
28. Weishaar RE, Burrows SD, Kobylarz DC, Quade MM, Evans DB (1986) Multiple molecular forms of cyclic nucleotide phosphodiesterase in cardiac and smooth muscle and in platelets. Isolation, characterization, and effects of various reference phosphodiesterase inhibitors and cardiotonic agents. Biochem Pharmacol 35:787-800